1. Home
  2. SKIL vs VERU Comparison

SKIL vs VERU Comparison

Compare SKIL & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skillsoft Corp.

SKIL

Skillsoft Corp.

HOLD

Current Price

$2.85

Market Cap

40.2M

Sector

Technology

ML Signal

HOLD

Logo Veru Inc.

VERU

Veru Inc.

SELL

Current Price

$2.09

Market Cap

41.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SKIL
VERU
Founded
1998
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.2M
41.9M
IPO Year
2019
1996

Fundamental Metrics

Financial Performance
Metric
SKIL
VERU
Price
$2.85
$2.09
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $25.67
AVG Volume (30 Days)
54.6K
★ 106.8K
Earning Date
12-09-2026
12-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$2.75
$2.04
52 Week High
$13.04
$7.33

Technical Indicators

Market Signals
Indicator
SKIL
VERU
Relative Strength Index (RSI) 21.09 40.86
Support Level N/A $2.09
Resistance Level $8.08 $2.68
Average True Range (ATR) 0.44 0.11
MACD -0.15 0.00
Stochastic Oscillator 1.91 26.67

Price Performance

Historical Comparison
SKIL
VERU

About SKIL Skillsoft Corp.

Skillsoft Corp is a leader in corporate digital learning. The company's segments include Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experiential learning platform that serves learners internationally. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: